144 related articles for article (PubMed ID: 31445736)
1. A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
Fang W; Huang Y; Gan J; Hong S; Zhang L
J Thorac Oncol; 2019 Sep; 14(9):e201-e202. PubMed ID: 31445736
[No Abstract] [Full Text] [Related]
2. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Lee Y; Kim TM; Kim DW; Kim S; Kim M; Keam B; Ku JL; Heo DS
J Thorac Oncol; 2019 Sep; 14(9):1556-1566. PubMed ID: 31108249
[TBL] [Abstract][Full Text] [Related]
4. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.
Dagogo-Jack I; Piotrowska Z; Cobb R; Banwait M; Lennerz JK; Hata AN; Digumarthy SR; Sequist LV
J Thorac Oncol; 2019 Oct; 14(10):e226-e228. PubMed ID: 31558234
[No Abstract] [Full Text] [Related]
5. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
6. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
White MN; Piotrowska Z; Stirling K; Liu SV; Banwait MK; Cunanan K; Sequist LV; Wakelee HA; Hausrath D; Neal JW
Clin Lung Cancer; 2021 May; 22(3):201-209. PubMed ID: 33610453
[TBL] [Abstract][Full Text] [Related]
7. Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing.
Zhou C; Zeng L; Zhang Y; Yang N
J Thorac Oncol; 2019 Jul; 14(7):e143-e144. PubMed ID: 31235037
[No Abstract] [Full Text] [Related]
8. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
[TBL] [Abstract][Full Text] [Related]
9. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
10. Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Tone M; Inomata M; Awano N; Kuse N; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Izumo T
Anticancer Res; 2020 Apr; 40(4):2239-2246. PubMed ID: 32234920
[TBL] [Abstract][Full Text] [Related]
11. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
[TBL] [Abstract][Full Text] [Related]
12. Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in
Girard N; Moro-Sibilot D; Bouée S; Emery C; Torreton E; Le Lay K; Luciani L; Maritaz C; Chouaid C
Future Oncol; 2020 Jun; 16(16):1115-1124. PubMed ID: 32352321
[No Abstract] [Full Text] [Related]
13. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
[TBL] [Abstract][Full Text] [Related]
14. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
15. Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.
Fang W; Gan J; Huang Y; Zhou H; Zhang L
J Thorac Oncol; 2019 Dec; 14(12):e274-e275. PubMed ID: 31757379
[No Abstract] [Full Text] [Related]
16. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
17. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE; Schoenfeld AJ; Makhnin A; Tobi Y; Wang Y; Frisco-Cabanos H; Chakrabarti S; Shi M; Napoli C; McDonald TO; Tan W; Hata A; Weinrich SL; Yu HA; Michor F
Nat Commun; 2021 Jun; 12(1):3697. PubMed ID: 34140482
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
19. Sequential afatinib and osimertinib in patients with
Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Märten A; Cufer T
Future Oncol; 2020 Dec; 16(34):2799-2808. PubMed ID: 32854536
[No Abstract] [Full Text] [Related]
20. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O; Kaira K; Kawasaki T; Mouri A; Hashimoto K; Shiono A; Shinomiya S; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Mochida S; Kagamu H
Thorac Cancer; 2020 Apr; 11(4):1045-1051. PubMed ID: 32068351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
